- Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) on Saturday, November 9, 2024 ROCKVILLE, Md., Oct. 30, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company exclusively focused on the...
I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024
Seaking AlphaSeeking Alpha / Seaking Alpha 15 hours ago 1 Views
Comments